Ευρωπαϊκή Ένωση - Αγγλικά - myHealthbox

eisai europe limited - perampanel - film-coated tablet - 6 mg - epilepsies, partial - antiepileptics, other antiepileptics - indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

Ευρωπαϊκή Ένωση - Αγγλικά - myHealthbox

eisai europe limited - perampanel - film-coated tablet - 8 mg - epilepsies, partial - antiepileptics, other antiepileptics - indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

Ευρωπαϊκή Ένωση - Αγγλικά - myHealthbox

eisai europe limited - perampanel - film-coated tablet - 10 mg - epilepsies, partial - antiepileptics, other antiepileptics - indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

Ευρωπαϊκή Ένωση - Αγγλικά - myHealthbox

eisai europe limited - perampanel - film-coated tablet - 12 mg - epilepsies, partial - antiepileptics, other antiepileptics - indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older

Ηνωμένο Βασίλειο - Αγγλικά - myHealthbox

claris lifesciences uk limited - zoledronic acid - concentrate for solution for infusion - 4mg/5ml - drugs for treatment of bone diseases, bisphosphonates - prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone. treatment of adult patients with tumour-induced hypercalcaemia (tih)

Ηνωμένο Βασίλειο - Αγγλικά - myHealthbox

glenmark pharmaceuticals europe limited - ezetimibe - tablets - 10mg - other lipid modifying agents - primary hypercholesterolaemia homozygous familial hypercholesterolaemia (hofh) homozygous sitosterolaemia (phytosterolaemia)

Ηνωμένο Βασίλειο - Αγγλικά - myHealthbox

milpharm limited - ribavirin - capsule, hard - 200mg - direct acting antivirals, nucleosides and nucleotides (excl.reverse transcriptase inhibitors) - adult patients: ribavirin is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis c except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (alt), who are positive for hepatitis c viral ribonucleic acid hcv-rna children 3 years of age and older and adolescents: ribavirin is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis c, except genotype 1, not previously treated, without liver decompensation, and who are positive for hcv-rna. when deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. the reversibility of growth inhibition is uncertain. the decision to treat should be made on a case by case basis

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

pacira limited - cytarabine - meningeal neoplasms - antineoplastic agents, - intrathecal treatment of lymphomatous meningitis. in the majority of patients such treatment will be part of symptomatic palliation of the disease.

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

jensonr+ limited - ivabradine hydrochloride - angina pectoris; heart failure - cardiac therapy - symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. ivabradine is indicated: - in adults unable to tolerate or with a contra-indication to the use of beta-blockers - or in combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. treatment of chronic heart failure ivabradine is indicated in chronic heart failure nyha ii to iv class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated.,

Ευρωπαϊκή Ένωση - Αγγλικά - EMA (European Medicines Agency)

pfizer limited - pneumococcal oligosaccharide serotype 18c, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 14 - pneumococcal infections; immunization - vaccines - active immunisation against disease caused by streptococcus pneumoniae serotypes 4, 6b, 9v, 14, 18c, 19f and 23f (including sepsis, meningitis, pneumonia, bacteraemia and acute otitis media) in infants and children from two months up to five years of age.the use of prevenar should be determined on the basis of official recommendations taking into consideration the impact of invasive disease in different age groups as well as variability of serotype epidemiology in different geographical areas.